Founded in 2006, Anthem Biosciences Limited is a technology and innovation-led Contract Research, Development, and Manufacturing Organization (CRDMO) with vertically integrated operations covering drug discovery, development, and manufacturing activities.

The company caters to varied customers such as innovative, early-stage biotech companies and big pharma companies globally.The company produces niche fermentation-based APIs, such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.For the half-year ended September 30, 2024, the company was involved in the production of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been funded since discovery.

The company had 196 projects as of September 30 2024: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).

As of March 31, 2024, and September 30, 2024, the company had more than 425 and 550 customers for our CRDMO and specialty ingredients business, distributed across more than 44 countries, including Europe, Japan, and the U.S.As of March 31, 2024, the company had more than 150 customers, ranging from small biotech to big pharma.As of 30 September 2024, the company has one patent in India, seven foreign, and 24 pending foreign patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.

As of 30 September 2024, the company has 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, specialists in different in-vivo non-clinical research and chemical engineers.